Is NVST a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Margin repair from a low base, with revenue (ttm) at ~$2.86 billion. The bear case rests on dental treatment is deferrable, and the 2024 collapse showed how fast patient traffic and practice capital budgets can move against this business. Analysts covering it are spread from $23.00 to $35.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Dental treatment is deferrable, and the 2024 collapse showed how fast patient traffic and practice capital budgets can move against this business. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $23.00, -16.8% from the $27.64 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Margin repair from a low base. Adjusted EBITDA margin moved from 11.8% in 2024 to 13.7% in 2025 and 14.7% in the second quarter of 2026, an expansion management credits to the Envista Business System, a 10% reduction in company-wide G&A, and the Spark aligner business reaching positive operating margin in the second half of 2025. The most optimistic analyst target on NVST is $35.00, +26.6% from the $27.64 price. That figure is only reachable if this thesis works close to its best case.

Dental treatment is deferrable, and the 2024 collapse showed how fast patient traffic and practice capital budgets can move against this business. Emerging markets, about 22% of 2025 sales, carry specific pricing pressure: China's volume-based procurement program has forced steep price cuts on dental consumables and implants, and first-half 2026 emerging-market core growth was 0.8% against 8.5% in developed markets. Goodwill and other intangibles still total roughly $3.0 billion on a $5.6 billion balance sheet after the 2024 write-down, so another demand shock could produce a second impairment. Following the April 2024 guidance withdrawal, several plaintiff law firms publicised investigations of potential securities claims; Envista's fiscal 2025 Form 10-K and its second-quarter 2026 Form 10-Q name no securities class action, state that legal proceedings have not materially changed, and carry a $26.3 million accrual covering all litigation matters combined. Roughly half of revenue is earned outside the United States and a single customer accounted for 13% of second-quarter sales, so currency translation and distributor inventory swings can each move reported results independently of underlying demand. The most pessimistic published target is $23.00, -16.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Envista Holdings is a dental products maker spun out of Danaher in 2019, selling implants, orthodontics and diagnostics through roughly 30 brands.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Margin repair from a low base) stalling in the reported numbers rather than in the narrative, the risk above (dental treatment is deferrable, and the 2024 collapse showed how fast patient traffic and practice capital budgets can move against this business) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Dental products, across about 30 brands sold in more than 130 countries. The lineup covers dental implants and prosthetics (Nobel Biocare, Implant Direct), orthodontic brackets and clear aligners (Ormco, Spark), digital imaging systems and software (DEXIS), and everyday clinical consumables such as bonding agents, cements, rotary burs, endodontic systems and infection prevention products (Kerr, Metrex). Roughly 85% of revenue comes from consumables, services and spare parts rather than one-off equipment sales.

NVST trades on the New York Stock Exchange as ordinary US common stock, so it can be bought at any US brokerage in whole or fractional shares during regular market hours. It is also held inside broad healthcare sector funds and US small- and mid-cap index funds, which provides indirect exposure without a single-stock position. Within Walnut, it can sit as one constituent of a thematic basket alongside other dental or medical device names, with a target weight set at the basket level.

Yes on both bases in the most recent periods, though the two diverge widely. Trailing twelve-month GAAP net income was about $95 million (~$0.58 diluted per share), while trailing adjusted diluted EPS was about $1.46. Full-year 2025 came in at $47 million of GAAP net income against $202 million of adjusted net income and $372 million of adjusted EBITDA. The 2024 fiscal year was a GAAP loss of $1.12 billion because of a $1.15 billion goodwill and intangible write-down.